Table 2Combination comparisons considered for review

MET + SUMET + MEGMET + DPP4MET + EXMET + BasalMET + premixedTZD + SUTZD + MEGTZD + DPP4TZD + EXTZD + basalTZD + premixedSU + MEGSU + DPP4SU + EXSU + BasalSU + premixedMEG + DPP4MEG + EXMEG + BasalMEG + premixedDPP4 + EXDPP4 + basal insDPP4 + premixedEX + basal insEX + premixed
MET + TZD
MET + SU
MET + MEG
MET + DPP4
MET + EX
MET + Basal
MET + premixed
TZD + SU
TZD + MEG
TZD + DPP4
TZD + EX
TZD + basal
TZD + premixed
SU + MEG
SU + DPP4
SU + EX
SU + basal
SU + premixed
MEG + DPP4
MEG + EX
MEG + basal
MEG + premixed
DPP4 + EX
DPP4 + basal
DPP4 + premixed
EX + basal

Black boxes indicate comparisons that were included in the review; light gray boxes indicate comparisons that were not included, but tallied; and dark gray boxes indicate comparisons that were excluded from the review.

AGI = alpha-glucosidase inhibitors; basal = basal insulin; BROMO = bromocriptine; COL = colesevalam; DPP4 = dipeptidyl peptidase-4 inhibitors; EX = exenatide; MEG = meglitinides; MET = metformin; premixed = premixed insulin; SU = sulfonylurea; TZD = thiazolidinedione

From: Appendix A, Medication Comparisons

Cover of Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update
Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update [Internet].
Comparative Effectiveness Reviews, No. 27.
Bennett WL, Wilson LM, Bolen S, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.